Steward Partners Investment Advisory’s Theravance Biopharma TBPH Stock Holding History

Steward Partners Investment Advisory’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,500	Closed	-$24.3K	–	4850
2026 Q1	$24.3K	Hold	1,500	–	–	﹤0.01%	3131
2025 Q4	$28.1K	Hold	1,500	–	–	﹤0.01%	2984
2025 Q3	$21.9K	Hold	1,500	–	–	﹤0.01%	3054
2025 Q2	$16.5K	Hold	1,500	–	–	﹤0.01%	2996
2025 Q1	$13.4K	Hold	1,500	–	–	﹤0.01%	2969
2024 Q4	$14.1K	Hold	1,500	–	–	﹤0.01%	2949
2024 Q3	$12.1K	Hold	1,500	–	–	﹤0.01%	2872
2024 Q2	$12.7K	Hold	1,500	–	–	﹤0.01%	2724
2024 Q1	$13.5K	Buy	+1,500	New	+$13.9K	﹤0.01%	2692
2020 Q4	–	Sell	-500	Closed	-$7K	–	2986
2020 Q3	$7K	Hold	500	–	–	﹤0.01%	2275
2020 Q2	$10K	Hold	500	–	–	﹤0.01%	2051
2020 Q1	$11K	Buy	+500	New	+$12.5K	﹤0.01%	1831

Other funds holding TBPH

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

ICM

Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Steward Partners Investment Advisory's TBPH Position: Q2 2026 in Review

Steward Partners Investment Advisory sold out of Theravance Biopharma (TBPH) in Q2 2026, closing a stake of 1,500 shares — an estimated $24.3K sold.

Steward Partners Investment Advisory first reported a position in TBPH in Q1 2020 and held it in 12 quarters. The position peaked at $28.1K in Q4 2025. 180 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

Steward Partners Investment Advisory reported no remaining Theravance Biopharma position as of Q2 2026 after selling out during the quarter.
Steward Partners Investment Advisory sold 1,500 Theravance Biopharma shares in Q2 2026, an estimated $24.3K.
Steward Partners Investment Advisory first reported a position in Theravance Biopharma in Q1 2020 and held it in 12 quarters.
Steward Partners Investment Advisory's Theravance Biopharma position peaked at $28.1K in Q4 2025.
180 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.